insightSLICE

Orphan Drugs Market

Orphan Drugs Market Size, Share, Sales, Analysis, Forecast by Disease Type (Oncologic Disease, Metabolic Disease, Hematologic and Immunologic Diseases, Infectious Diseases, Neurologic Diseases and Other Rare Diseases), By Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma and Others), By Therpay (Oncology, Blood, Central Nervous System, Endocrine, Cardiovascular and Respiratory), By Sale (Generics and Prescribed), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online) Industry Competition & Player Profiles, 2023 – 2032
Frequently asked questions about this report

Rising prevalence of rare diseases, and the surge in the investments in the avenues related to the research and development going in to these conditions, are anticipated to boost the orphan drugs market.

The global orphan drugs market segmented on the basis of indication, therapy class, drug, disease type, drug type, sale, distribution channel, and geography.

AbbVie Inc., Aegerion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Pfizer Inc. and Sanofi, Boehringer Ingelheim GmbH, Amgen Inc., Biogen Idec, Actelion Pharmaceuticals Ltd, AstraZeneca plc, Janssen Biotech, Inc. among others, are the major players in this market.

The base year considered in orphan drugs market report is 2022.

North America is anticipated to continue to dominate the regional market for orphan pharmaceuticals worldwide.

The orphan drugs market size was estimated to be US$ 160.5 billion in 2021.

The orphan drugs market is estimated to exhibit a CAGR of 9.5% through 2032.